Search

Your search keyword '"Ferrara M. A."' showing total 50 results
Start Over Author "Ferrara M. A." Publisher elsevier ltd
50 results on '"Ferrara M. A."'

6. Elucidating the role of baseline and on-treatment nutritional status and body composition on clinical outcomes in advanced nsclc patients treated with immunotherapy

Author

Mentrasti, G., Lunetti, S., Pecci, F., Mignini, V.E., Cola, C., Ferrara, M., Chiariotti, R., De Filippis, C., Temperoni, L. Angeli, Copparoni, C., Cognigni, V., Bruschi, G., Gualtieri, M., Lunerti, V., Santamaria, L., Agostinelli, V., Paoloni, F., Chiodi, N., Cantini, L., Burattini, L., Taus, M., and Berardi, R.

Published
2024
Full Text
View/download PDF

7. 1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)

Author

Nuccio, A., Salomone, F., Viscardi, G., Venanzi, F.M., Bulotta, A., Ogliari, F.R., Oresti, S., Riva, S.T., Mollica, L., Viganò, M.G., Passaretti, F., Ravasi, M., Papotto, L., Ferrara, M., Ricciuti, B., Veronesi, G., Cascone, T., Garassino, M.C., Torri, V., and Ferrara, R.

Published
2024
Full Text
View/download PDF

9. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

Author

Buti, S, Bersanelli, M, Perrone, F, Bracarda, S, Di Maio, M, Giusti, R, Nigro, O, Cortinovis, D, Aerts, J, Guaitoli, G, Barbieri, F, Ferrara, M, Bria, E, Grossi, F, Bareggi, C, Berardi, R, Torniai, M, Cantini, L, Sforza, V, Genova, C, Chiari, R, Rocco, D, Della Gravara, L, Gori, S, De Tursi, M, Di Marino, P, Mansueto, G, Zoratto, F, Filetti, M, Citarella, F, Russano, M, Mazzoni, F, Garassino, M, De Toma, A, Signorelli, D, Gelibter, A, Siringo, M, Follador, A, Bisonni, R, Tuzi, A, Minuti, G, Landi, L, Ricciardi, S, Migliorino, M, Tabbò, F, Olmetto, E, Metro, G, Adamo, V, Russo, A, Spinelli, G, Banna, G, Addeo, A, Friedlaender, A, Cannita, K, Porzio, G, Ficorella, C, Carmisciano, L, Pinato, D, Mazzaschi, G, Tiseo, M, Cortellini, A, Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis D, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A, Buti, S, Bersanelli, M, Perrone, F, Bracarda, S, Di Maio, M, Giusti, R, Nigro, O, Cortinovis, D, Aerts, J, Guaitoli, G, Barbieri, F, Ferrara, M, Bria, E, Grossi, F, Bareggi, C, Berardi, R, Torniai, M, Cantini, L, Sforza, V, Genova, C, Chiari, R, Rocco, D, Della Gravara, L, Gori, S, De Tursi, M, Di Marino, P, Mansueto, G, Zoratto, F, Filetti, M, Citarella, F, Russano, M, Mazzoni, F, Garassino, M, De Toma, A, Signorelli, D, Gelibter, A, Siringo, M, Follador, A, Bisonni, R, Tuzi, A, Minuti, G, Landi, L, Ricciardi, S, Migliorino, M, Tabbò, F, Olmetto, E, Metro, G, Adamo, V, Russo, A, Spinelli, G, Banna, G, Addeo, A, Friedlaender, A, Cannita, K, Porzio, G, Ficorella, C, Carmisciano, L, Pinato, D, Mazzaschi, G, Tiseo, M, Cortellini, A, Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis D, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, and Cortellini A

Abstract

Background: We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic score to be calculated before immunotherapy initiation in patients with advanced solid tumours. This ‘drug score’ was calculated assigning score 1 for each between proton-pump inhibitor and antibiotic administration until a month before cancer therapy initiation and score 2 in case of corticosteroid intake. The good risk group included patients with score 0, intermediate risk with score 1–2 and poor risk with score 3–4. Methods: Aiming at validating the prognostic and putative predictive ability depending on the anticancer therapy, we performed the present comparative analysis in two cohorts of advanced non–small-cell lung cancer (NSCLC), respectively, receiving first-line pembrolizumab or chemotherapy through a random case-control matching and through a pooled multivariable analysis including the interaction between the computed score and the therapeutic modality (pembrolizumab vs chemotherapy). Results: Nine hundred fifty and 595 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. After the case-control random matching, 589 patients from the pembrolizumab cohort and 589 from the chemotherapy cohort were paired, with no statistically significant differences between the characteristics of the matched subjects. Among the pembrolizumab-treated group, good, intermediate and poor risk evaluable patients achieved an objective response rate (ORR) of 50.0%, 37.7% and 23.4%, respectively, (p < 0.0001), whereas among the chemotherapy-treated group, patients achieved an ORR of 37.0%, 40.0% and 32.4%, respectively (p = 0.4346). The median progression-free survival (PFS) of good, intermediate and poor risk groups was 13.9 months, 6.3 months and 2.8 months, respectively, within the pembrolizumab coh

Published
2021

12. T02.01.18 USE OF PROBIOTICS IN THE HELICOBACTER PYLORI ERADICATION IN ITALY: DATA FROM THE “ITALIAN REGISTRY” ON H. PYLORI TREATMENT

Author

Zagari, R.M., Romiti, A., Saracino, I.M., Ribaldone, D., Panarese, A., Lella, F., Gigliotti, F., Gasbarrini, A., Del Vecchio Blanco, G., Paoluzi, O.A., Romano, M., Annibale, B., Broglia, L., Catanzaro, R., Marfinati Hervoso, C., Luzza, F., Nardone, G., Grande, G., Conigliaro, R., Cannizzaro, R., Fiorini, G., Pavoni, M., Vaira, B., Pellicano, R., Ferrara, M., and Bazzoli, F.

Published
2020
Full Text
View/download PDF

13. P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

Author

Tabernero, J., Fernandez, E. Elez, Ghiringhelli, F., Folprecht, G., Curigliano, G., Siena, S., Cremolini, C., Sobrero, A., Kwiatek, M., Keränen, S. Roselló, Ahn, D., Punt, C., Laurent, D., Ferrara, M., Pellacani, A., and Capriati, A.

Published
2020
Full Text
View/download PDF

17. P.01.32 PROBIOTIC SUPPLEMENTATION IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT

Author

Zagari, R.M., Romiti, A., Saracino, I.M., Ribaldone, D.G., Gigliotti, F., Lella, F., Avallone, L., Annibale, B., Hervoso, C. Marfinati, Grande, G., Luzza, F., Broglia, L., Gasbarrini, A., Catanzaro, R., Cannizzaro, R., Nardone, G., Panarese, A., Del Vecchio Blanco, G., Vaira, B., Pellicano, R., Ferrara, M., Romano, M., Conigliaro, R.L., Stanghellini, V., and Bazzoli, F.

Published
2019
Full Text
View/download PDF

18. P.01.14 CURRENT PRACTICE OF GASTROENTEROLOGISTS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT

Author

Zagari, R.M., Romiti, A., Saracino, I.M., Ribaldone, D.G., Gigliotti, F., Lella, F., Avallone, L., Annibale, B., Hervoso, C. Marfinati, Grande, G., Luzza, F., Broglia, L., Gasbarrini, A., Catanzaro, R., Cannizzaro, R., Nardone, G., Panarese, A., Del Vecchio Blanco, G., Vaira, B., Pellicano, R., Ferrara, M., Romano, M., Conigliaro, R., Stanghellini, V., and Bazzoli, F.

Published
2019
Full Text
View/download PDF

20. Electrical stimulation of the frontal cortex enhances slow-frequency EEG activity and sleepiness

Author

D'Atri, A., De Simoni, E., Gorgoni, Marcello, Ferrara, M., Ferlazzo, F., Rossini, Paolo Maria, De Gennaro, L., Rossini, Paolo Maria (ORCID:0000-0003-2665-534X), D'Atri, A., De Simoni, E., Gorgoni, Marcello, Ferrara, M., Ferlazzo, F., Rossini, Paolo Maria, De Gennaro, L., and Rossini, Paolo Maria (ORCID:0000-0003-2665-534X)

Abstract

Our aim was to enhance the spontaneous slow-frequency EEG activity during the resting state using oscillating transcranial direct currents (tDCS) with a stimulation frequency that resembles the spontaneous oscillations of sleep onset. Accordingly, in this preliminary study, we assessed EEG after-effects of a frontal oscillatory tDCS with different frequency (0.8 vs. 5 Hz) and polarity (anodal, cathodal, and sham).Two single-blind experiments compared the after effects on the resting EEG of oscillatory tDCS [Exp. 1 = 0.8 Hz, 10 subjects (26.2 ± 2.5 years); Exp. 2 = 5 Hz, 10 subjects (27.4 ± 2.4 years)] by manipulating its polarity.EEG signals recorded (28 scalp derivations) before and after stimulation [slow oscillations (0.5-1 Hz), delta (1-4 Hz), theta (5-7 Hz), alpha (8-12 Hz), beta 1 (13-15 Hz) and beta 2 (16-24 Hz)] were compared between conditions as a function of polarity (anodal vs. cathodal vs. sham) and frequency of stimulation (0.8 vs. 5 Hz).We found a significant relative enhancement of the delta activity after the anodal tDCS at 5 Hz compared to that at 0.8 Hz. This increase, even though not reaching the statistical significance compared to sham, is concomitant to a significant increase of subjective sleepiness, as assessed by a visual analog scale. These two phenomena are linearly related with a regional specificity, correlations being restricted to cortical areas perifocal to the stimulation site.We have shown that a frontal oscillating anodal tDCS at 5 Hz results in an effective change of both subjective sleepiness and spontaneous slow-frequency EEG activity. These changes are critically associated to both stimulation polarity (anodal) and frequency (5 Hz). However, evidence of frequency-dependence seems more unequivocal than evidence of polarity-dependence.

Published
2016

24. Food allergy in Italian paediatric population: Preliminary results of a nationwide study on prevalence, clinical characteristics and common diagnostic approaches

Author

Tardi, M., Guariso, G., Ruotolo, S., Castaldo, A., Florio, G., Liberatore, G., Gasparini, N., Occhinegro, A., Ruggiero, G., D’Agostino, E., Ferrara, M., Russomando, M., Moragni, L., Mongibello, A.P., Frezzetti, A., Ferraro, L., Nichetti, C., Cosenza, L., Troncone, R., and Canani, R. Berni

Published
2007
Full Text
View/download PDF

27. List of contributors

Author

Brennan, L., Capozzi, F., Dragsted, L.O., Ferrara, M., Han, X., Holmes, E., Jia, W., Jourdan, F., Manach, C., Polakof, S., Poupin, N., Richards, S.E., Sébédio, J.-L., Trimigno, A., Xie, G., and Zhou, Y.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results